Global Hodgkin Lymphoma Treatment Market 2020-2026
発行: Orion Market Research Pvt Ltd
Global Hodgkin Lymphoma Treatment Market Size, Share & Trends Analysis Report, by Type (Radiation therapy, Immunotherapy, Chemotherapy, and Others), and Forecast Period, 2020-2026.
The global Hodgkin lymphoma treatment market is estimated to grow significantly during the forecast period. Hodgkin lymphoma is cancer originates from specific white blood cells (WBC), also known as lymphocytes. Symptoms such as fever, weight loss and night sweat are some non-painful enlarged nodes generally took place under the arm, the neck and in the inguinal region. The growing demand for advanced Hodgkin lymphoma treatment along with a high acceptance rate in developed nations and an increase in awareness about the Hodgkin lymphoma diagnosis is fueling the market growth during the forecast period. According to the National Cancer Institute (NCI), more than 8,000 people in the US were diagnosed with Hodgkin lymphoma in 2017. Hence, a growing number of diagnoses will create demand for efficient treatment which will boost the Hodgkin lymphoma treatment market.
The global Hodgkin lymphoma treatment market is segmented based on type. Based on type, the market is classified into radiation therapy, immunotherapy, chemotherapy, and others (stem cell transplant). There are various drugs available in the market for the treatment of Hodgkin lymphoma. These drugs include Adcetris (Brentuximab Vedotin), BiCNU (Carmustine), Brentuximab Vedotin, Carmustine, Cyclophosphamide, Dacarbazine, Adriamycin (doxorubicin), Bleomycin, Vinblastine and Dacarbazine (DTIC).
Geographically, the global Hodgkin lymphoma treatment market is classified into North America, Europe, Asia-Pacific, and the Rest of the world. North America is estimated to witness significant growth in the market and is expected to retain its dominance in the coming years. The major companies providing Hodgkin lymphoma treatment include Bristol-Myers Squibb Co., Pfizer, Inc., Hikma Pharmaceuticals PLC, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., Fresenius Kabi USA, LLC, Genentech Inc., Leadiant Biosciences, Inc., and LGM Pharma, LLC.
The market study of the global Hodgkin lymphoma treatment market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
The Report Covers: